ریکٹل کینسر (Rectal cancer)
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
کہاں جانا ہے
اس ٹرائل کے لیے انڈیا کے 5 ہسپتال مریض لے رہے ہیں۔
رجسٹری کی سمری (ٹیکنیکل)
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxaliplatin (mFOLFOX6) or 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus cetuximab and mFOLFOX6 or FOLFIRI in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS)/ Neuroblastoma RAS viral oncogene homolog (NRAS) and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) wild type…
Sponsor: Janssen Research & Development, LLC
ClinicalTrials.gov پر NCT06662786
رجسٹری میں آخری بار 25 Sep 2026 کو اپڈیٹ کیا گیا · ہم نے 20 Oct 2026 کو پڑھا